Valion Bio's Entolimod™ Program Receives $7M NIAID Funding, Federal Agency to Co-Navigate FDA Submission
VBIO sits 51% above its 52-week low of $0.722.
Summary
Valion Bio has received the first FDA-precedent study protocol from the National Institute of Allergy and Infectious Diseases (NIAID) for its Entolimod™ program. Critically, NIAID will fully fund up to $7 million for the BLA-enabling in vivo studies, representing a substantial non-dilutive financial injection for the company. Furthermore, NIAID will co-navigate the FDA submission process, significantly de-risking the regulatory pathway for Entolimod™. This development provides a major boost to the program's advancement and financial stability, representing a highly material positive catalyst for Valion Bio.
At the time of this announcement, VBIO was trading at $1.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3M. The 52-week trading range was $0.72 to $5.60. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.